Hikma agrees $50m settlement for Xyrem class actions
8th May 2025 08:56
(Sharecast News) - Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves the majority of its Xyrem (sodium oxybate) antitrust class action cases in the US.
Read moreLondon close: Stocks manage small gains after US jobless claims
24th Apr 2025 15:32
(Sharecast News) - London stocks ended marginally higher on Thursday, recovering from earlier losses as investors assessed fresh signals on the health of the US labour market.
Read moreHikma Pharmaceuticals reaffirms guidance after solid start to year
24th Apr 2025 07:57
(Sharecast News) - Hikma Pharmaceuticals reaffirmed its full-year guidance on Thursday following a solid start to 2025, supported by stable trading across its three core divisions.
Read moreLondon close: Stocks rise as investors look to Nvidia earnings
26th Feb 2025 15:04
(Sharecast News) - London stocks ended higher on Wednesday, with investors maintaining a cautious yet positive stance ahead of Nvidia's earnings release in the United States later in the global day.
Read moreShares in Hikma fall after results disappoint
26th Feb 2025 08:51
(Sharecast News) - Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after core operating profits and a weaker margin disappointed.
Read moreLondon close: Stocks finish lower as Ashtead announces US move
10th Dec 2024 16:03
(Sharecast News) - London stocks closed in negative territory on Tuesday, weighed down by a dip in sentiment following news that Ashtead planned to shift its primary listing to the United States, adding to a growing trend of London-listed firms looking across the Atlantic.
Read moreRBC upgrades Hikma Pharmaceuticals to 'outperform'
10th Dec 2024 08:02
(Sharecast News) - Analysts at RBC Capital Markets upgraded Hikma Pharmaceuticals from 'sector perform' to 'outperform' on Tuesday as it took a look at the wider European pharmaceutical and biotechnology sector.
Read moreHikma reiterates outlook on strong trading
7th Nov 2024 08:19
(Sharecast News) - Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.
Read moreHikma engages shareholders over buyback waiver
24th Oct 2024 08:52
(Sharecast News) - Hikma Pharmaceuticals updated the market over the significant opposition to a resolution at its annual general meeting on Thursday.
Read moreLondon close: Stocks slip as investors digest UK, US data
3rd Sep 2024 15:51
(Sharecast News) - London stocks ended Tuesday in negative territory as investors reacted to the latest UK retail sales date, and a fresh manufacturing sector reading out of the US.
Read moreBerenberg upgrades Hikma Pharmaceuticals to 'buy'
3rd Sep 2024 09:44
(Sharecast News) - Berenberg upgraded Hikma Pharmaceuticals on Tuesday and lifted the price target to 2,400p from 2,100p as it said "clear progress" had been made.
Read moreLondon close: Stocks buoyed by solid economic data
15th Aug 2024 15:30
(Sharecast News) - London stocks ended Thursday on a positive note, buoyed by data confirming expected growth in the UK economy for the second quarter.
Read moreBerenberg raises target price on Hikma Pharmaceuticals following H1 results
13th Aug 2024 09:13
(Sharecast News) - Analysts at Berenberg raised their target price on Hikma Pharmaceuticals from 2,000.0p to 2,100.0p on Tuesday following an "impressive" H1 performance.
Read moreLondon close: Stocks claw back losses but still finish lower
8th Aug 2024 14:57
(Sharecast News) - London markets ended Thursday on a weaker note despite recovering some earlier losses, as concerns over a potential US recession weighed on investor sentiment.
Read moreHikma Pharmaceuticals outlines 'excellent' H1, upgrades FY guidance
8th Aug 2024 08:02
(Sharecast News) - Pharmaceutical company Hikma Pharmaceuticals shares were in the green early on Thursday after the group's H1 results pointed to an "excellent" start to the year and upgraded FY guidance.
Read more